Robert Orlowski, Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared on X:
“Myeloma Paper of the Day:
Limited duration (≤3 months) of dexamethasone in newly diagnosed AL amyloidosis (w/ daratumumab-based regimen) results in higher 6-month CR rates (66.7 vs 30.4%, p<0.001) and reduced toxicity, similar organ responses.”
Title: Limited duration of dexamethasone in newly diagnosed AL amyloidosis: impact on response, toxicity, and survival
Authors: John Hanna, Hong Li, Ryan Brown, Zain Ali Burney, Kawther Abdallah, Diana Basali, Jason Valent, Christy Samaras, Faiz Anwer, Jack Khouri, Shahzad Raza, Willem Van Heeckeren, Mazen Hanna, J. Emanuel Finet, Louis Williams, Sandy Mazzoni
You can read the full article on Hematology.
You can find other articles featuring Robert Orlowski on OncoDaily.
